DOACT Algorithm Versus AI-Based Decision Models in Oral Anticoagulant Therapy for Vascular Patients
NCT ID: NCT07290608
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
59 participants
INTERVENTIONAL
2025-01-20
2025-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DOACT algorithm
Use of DOACT algorithm (Dose-Oriented Anticoagulant Calculator for Evidence-Based Decision Tool) to recommend appropriate oral anticoagulant regimens.
DOACT algorithm
Vascular and non-vascular physicians using DOACT (Dose-Oriented Anticoagulant Calculator for Evidence-Based Decision Tool) to recommend appropriate oral anticoagulant regimens-dose selection and duration responding 15 standardized clinical case vignettes representing patients with vascular diseases such as deep vein thrombosis (DVT), superficial thrombophlebitis, and pulmonary thromboembolism (PTE).
No algorithm
Standard clinical decision-making to recommend appropriate oral anticoagulant regimens.
No algorithm
Vascular and non-vascular physicians using standard clinical decision-making (no use of algorithm) to recommend appropriate oral anticoagulant regimens-dose selection and duration responding 15 standardized clinical case vignettes representing patients with vascular diseases such as deep vein thrombosis (DVT), superficial thrombophlebitis, and pulmonary thromboembolism (PTE).
LLM-based tools
Use of large language model (LLM)-based tools to recommend appropriate oral anticoagulant regimens.
LLM-based tools
Vascular and non-vascular physicians using large language model (LLM)-based tools to recommend appropriate oral anticoagulant regimens-dose selection and duration responding 15 standardized clinical case vignettes representing patients with vascular diseases such as deep vein thrombosis (DVT), superficial thrombophlebitis, and pulmonary thromboembolism (PTE).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DOACT algorithm
Vascular and non-vascular physicians using DOACT (Dose-Oriented Anticoagulant Calculator for Evidence-Based Decision Tool) to recommend appropriate oral anticoagulant regimens-dose selection and duration responding 15 standardized clinical case vignettes representing patients with vascular diseases such as deep vein thrombosis (DVT), superficial thrombophlebitis, and pulmonary thromboembolism (PTE).
No algorithm
Vascular and non-vascular physicians using standard clinical decision-making (no use of algorithm) to recommend appropriate oral anticoagulant regimens-dose selection and duration responding 15 standardized clinical case vignettes representing patients with vascular diseases such as deep vein thrombosis (DVT), superficial thrombophlebitis, and pulmonary thromboembolism (PTE).
LLM-based tools
Vascular and non-vascular physicians using large language model (LLM)-based tools to recommend appropriate oral anticoagulant regimens-dose selection and duration responding 15 standardized clinical case vignettes representing patients with vascular diseases such as deep vein thrombosis (DVT), superficial thrombophlebitis, and pulmonary thromboembolism (PTE).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently practicing clinical and/or surgical vascular care in Brazil.
* Completed the informed consent process (TCLE) and voluntarily agreed to participate.
* Free-access LLMs available to the public at the time of data collection.
* All responses generated using the same standardized prompt.
* Capable of producing complete, text-based clinical answers relevant to vascular surgery decision-making.
Exclusion Criteria
* Physicians not performing vascular clinical or surgical care (e.g., exclusively administrative, academic, or non-assistance roles).
* Less than 1 year of professional experience after medical school graduation.
* Did not sign or did not fully complete the TCLE.
Large Language Models (LLMs)
* Paid or subscription-based LLMs.
* LLMs requiring institutional licenses, restricted access, or proprietary tokens.
* Models unable to generate full responses to the standardized prompt.
18 Years
89 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ITALO EUGENIO SOUZA GADELHA DE ABREU
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ITALO EUGENIO SOUZA GADELHA DE ABREU
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Irmandade da Santa Casa de Misericórdia de São Paulo
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gee E. The National VTE Exemplar Centres Network response to implementation of updated NICE guidance: venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89). Br J Haematol. 2019 Sep;186(5):792-793. doi: 10.1111/bjh.16010. Epub 2019 Jun 5. No abstract available.
Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018 Jul 4;362:k2505. doi: 10.1136/bmj.k2505.
Nielsen PB, Lundbye-Christensen S, Rasmussen LH, Larsen TB. Improvement of anticoagulant treatment using a dynamic decision support algorithm: a Danish Cohort study. Thromb Res. 2014 Mar;133(3):375-9. doi: 10.1016/j.thromres.2013.12.042. Epub 2014 Jan 7.
Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, Ten Cate-Hoek AJ, Elalamy I, Enzmann FK, Geroulakos G, Gottsater A, Hunt BJ, Mansilha A, Nicolaides AN, Sandset PM, Stansby G, Esvs Guidelines Committee, de Borst GJ, Bastos Goncalves F, Chakfe N, Hinchliffe R, Kolh P, Koncar I, Lindholt JS, Tulamo R, Twine CP, Vermassen F, Wanhainen A, Document Reviewers, De Maeseneer MG, Comerota AJ, Gloviczki P, Kruip MJHA, Monreal M, Prandoni P, Vega de Ceniga M. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021 Jan;61(1):9-82. doi: 10.1016/j.ejvs.2020.09.023. Epub 2020 Dec 15. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DOACT-AI-VASC Study
Identifier Type: -
Identifier Source: org_study_id